To achieve our goals of bringing safe and effective medicines to patients in need, as well as achieving long-term growth, Daiichi Sankyo partners with a variety of organizations to focus on progressing promising products that complement our in-house portfolio.

Our strategy involves in-licensing new products and product candidates, acquiring companies that will drive our portfolio in key therapeutic areas, as well as partnering on specific aspects of research, development and/or commercialization.

Our decades-long history of effective collaboration exemplifies our ability to license products in and out of Daiichi Sankyo, develop and maintain valuable partnerships, and successfully complete mergers and acquisitions.

Here is a snapshot of our activity:

Partner Press Release Summary
Partnering of ADC including combination studies AstraZeneca Aug. 2020 Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer
AstraZeneca Jul. 2020 Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062
Gustave Roussy Jul. 2020 Daiichi Sankyo and Gustave Roussy Enter Innovative Research Collaboration for DXd ADCs DS-1062 and Patritumab Deruxtecan
Merck & Co., Inc. Jun. 2020 Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Non-Small Cell Lung Cancer
AstraZeneca Mar. 2019 Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo’s HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201)
Merck & Co., Inc. Sep. 2018 Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-8201 in Combination with KEYTRUDA® (pembrolizumab) in HER2 Expressing Breast and HER2 Expressing or HER2 Mutant Lung Cancers
Bristol-Myers Squibb Aug. 2017 Bristol-Myers Squibb and Daiichi Sankyo Announce Research Collaboration to Evaluate Opdivo® (nivolumab) and DS-8201 in HER2-Expressing Breast and Bladder Cancers
In-License Eli Lilly  Aug. 2021 Eli Lilly Japan and Daiichi Sankyo Enter a Collaborative Agreement to Commercialize Lasmiditan Succinate in Japan for the Acute Treatment of Migraines
Esperion Apr. 2021 Daiichi Sankyo Enters into Licensing Agreement with Esperion to Market Hypercholesterolemia Treatment in Asia and South America
Eli Lilly Oct. 2020 Eli Lilly and Daiichi Sankyo Enter Commercialization Collaboration in Japan for Anti-CGRP Antibody Galcanezumab
Esperion Jan. 2019 Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet
Kite Pharma a subsidary of Gilead Sciences Jan. 2017 Daiichi Sankyo Establishes Strategic Partnership for Cellular Therapy Pipeline with Kite Pharma
Out-license Alfresa Pharma  Feb. 2021 Daiichi Sankyo Announces Split off (Simple Absorption-type Split) and Transfer of 11 Long-listed Products in Japan
AnHeart Therapeutics Dec. 2018 Daiichi Sankyo Out-Licenses ROS1/NTRK Inhibitor DS-6051 to AnHeart Therapeutics
Boston Pharmaceuticals Aug. 2017 Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitorfor Solid Tumors
Oncology Research Collaboration LYSA-LYSARC-CALYM Feb. 2021 Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with Relapsed/Refractory B-Cell Lymphoma
Sarah Cannon Research Institute Dec. 2018 Daiichi Sankyo and Sarah Cannon Research Institute Launch Strategic Collaboration to Develop Novel Cancer Therapies
Zymeworks May 2018 Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies
DarwinHealth Apr. 2018 Daiichi Sankyo and DarwinHealth Enter Exclusive Research Collaboration for Novel Cancer Target Initiative
Puma Biotechnology Dec. 2017 Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
MD Anderson Cancer Center Sep. 2017 MD Anderson and Daiichi Sankyo Enter Research Collaboration to Accelerate Development of Acute Myeloid Leukemia Therapies
Max Planck Innovation and Lead Discovery Center Jul. 2017 Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration
Specialty Medicines Gene Therapy Manufacturing Collaboration Ultragenyx Apr. 2020 Daiichi Sankyo Enters into Strategic Partnership with Ultragenyx for Use of Gene Therapy Manufacturing Technology